Nebivolol Comp. Ratiopharm (Hydrochlorothiazide, Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractility. It also enhances nitric‑oxide release from the endothelium, causing vasodilation. This dual action lowers systemic vascular resistance and contributes to overall blood‑pressure reduction.

The dosage of Nebivolol Comp. Ratiopharm is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure profile, renal function, and other clinical factors. Patients should follow the exact regimen provided by their prescriber and not adjust the dose on their own.

Safety data for nebivolol and hydrochlorothiazide during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with single‑agent therapies, the nebivolol/hydrochlorothiazide combination offers both β‑blockade and diuretic effects in one tablet, which can simplify regimens and improve adherence. It may be preferred when a patient needs both heart‑rate control and volume reduction, whereas other classes such as ACE inhibitors or ARBs act through different pathways.

Store the tablets at room temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure they are out of reach of children. Do not use the product after the expiry date printed on the packaging.

Nebivolol Comp. Ratiopharm is taken orally, usually once daily with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe hypotension, electrolyte disturbances such as low potassium, acute kidney injury, and rare allergic reactions like angioedema. Patients should seek immediate medical attention if they experience fainting, rapid weight loss, swelling, rash, or difficulty breathing.

The medication is contraindicated in patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any excipients, as well as those with severe bradycardia, uncontrolled heart failure, or significant electrolyte imbalances. Caution is also advised for individuals with asthma, severe liver disease, or chronic kidney disease.